Ionis’ olezarsen meets primary endpoint in Phase 3 FCS patient trial
In the study, the results showed a statistically significant reduction in TG levels with the olezarsen 80 mg…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Sep 23
In the study, the results showed a statistically significant reduction in TG levels with the olezarsen 80 mg…
27 Sep 23
As per the agreement, CSL Seqirus will be on standby to produce more than 100 million registered influenza…
27 Sep 23
The contract testing, development and manufacturing organisation (CTDMO) will now provide integrated services for all key phases of…
27 Sep 23
The DP facility is equipped with an automatic vial washing, sterilizing, filling and capping line, which can support…
26 Sep 23
Valo will receive an upfront payment and a potential near-term milestone payment, totalling $60m, and is eligible to…
26 Sep 23
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of…
25 Sep 23
Under the expanded partnership, scientists at the ICR’s Centre for Cancer Drug Discovery will work with researchers at…
25 Sep 23
Compared to chemotherapy, the combination met its dual primary endpoints of overall survival and progression-free survival showing a…
25 Sep 23
Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Sep 23
Situated in IDA Business Park in Clonshaugh, the site will serve as an international base for a line…